Literature DB >> 12867596

Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation.

Toru Kumagai1, Makoto Katsumata, Akihiro Hasegawa, Keiji Furuuchi, Toshiki Funakoshi, Ichiro Kawase, Mark I Greene.   

Abstract

We investigated the assembly and activation of the epidermal growth factor receptor (EGFR)-p185c-neu heterodimer by using a sequential immunoprecipitation methodology. Using this approach we detected heterodimers and also higher-ordered oligomeric complexes. Phosphorylated EGFR-p185c-neu heterodimeric forms were detected in the absence of EGF, but the species became highly phosphorylated after EGF stimulation. To evaluate heterodimer formation and additional transactivation by EGF, we investigated the roles of the four extracellular subdomains of p185c-neu and the EGFR. Subdomains I-IV of the EGFR dimerized with subdomains I-IV of p185c-neu, respectively, in a parallel manner. In addition, subdomains I-IV of the EGFR also associated with p185c-neu subdomains III, IV, I, and II, respectively. A lack of one of the p185c-neu cysteine-rich domains (subdomains II or IV) resulted in a loss of EGF-induced transactivation. These data suggest that two cysteine-rich domains play defining roles in ligand-dependent transactivation and that both of these cysteine-rich extracellular subdomains as well as non-cysteine-rich extracellular subdomains are involved in ligand-independent interactions with the EGFR. Our studies provide biochemical evidence of the role of the cysteine-rich domains of p185c-neu in assembly and transactivation of erbB complexes and also indicate that these subdomains might be useful clinical targets.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12867596      PMCID: PMC170899          DOI: 10.1073/pnas.1633546100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.

Authors:  D B Weiner; J Liu; J A Cohen; W V Williams; M I Greene
Journal:  Nature       Date:  1989-05-18       Impact factor: 49.962

3.  The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling.

Authors:  T Kumagai; J G Davis; T Horie; D M O'Rourke; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

4.  The neu oncogene encodes an epidermal growth factor receptor-related protein.

Authors:  C I Bargmann; M C Hung; R A Weinberg
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

5.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

Authors:  T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

6.  Disabling receptor ensembles with rationally designed interface peptidomimetics.

Authors:  Alan Berezov; Jinqiu Chen; Qingdu Liu; Hong-Tao Zhang; Mark I Greene; Ramachandran Murali
Journal:  J Biol Chem       Date:  2002-05-14       Impact factor: 5.157

7.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.

Authors:  C Wright; B Angus; S Nicholson; J R Sainsbury; J Cairns; W J Gullick; P Kelly; A L Harris; C H Horne
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

8.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

9.  Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells.

Authors:  P P Di Fiore; J H Pierce; T P Fleming; R Hazan; A Ullrich; C R King; J Schlessinger; S A Aaronson
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

10.  Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor.

Authors:  Y Yarden; J Schlessinger
Journal:  Biochemistry       Date:  1987-03-10       Impact factor: 3.162

View more
  9 in total

1.  Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.

Authors:  Sashikanth Banappagari; Miriam Corti; Seth Pincus; Seetharama Satyanarayanajois
Journal:  J Biomol Struct Dyn       Date:  2012-06-26

2.  Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.

Authors:  Goldi A Kozloski; Coralie A Carothers Carraway; Kermit L Carraway
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

3.  Molecular modeling of nearly full-length ErbB2 receptor.

Authors:  Péter Bagossi; Gábor Horváth; György Vereb; János Szöllösi; József Tözsér
Journal:  Biophys J       Date:  2004-12-13       Impact factor: 4.033

4.  A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein.

Authors:  Sashikanth Banappagari; Sharon Ronald; Seetharama D Satyanarayanajois
Journal:  J Biomol Struct Dyn       Date:  2010-12

5.  Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer.

Authors:  Shanthi Kanthala; Sashikanth Banappagari; Ameya Gokhale; Yong-Yu Liu; Gu Xin; Yunfeng Zhao; Seetharama Jois
Journal:  Chem Biol Drug Des       Date:  2014-11-06       Impact factor: 2.817

6.  Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain.

Authors:  Sashikanth Banappagari; Alecia McCall; Krystal Fontenot; M Graca H Vicente; Amit Gujar; Seetharama Satyanarayanajois
Journal:  Eur J Med Chem       Date:  2013-04-28       Impact factor: 6.514

7.  Estrogen receptor-alpha mediates the epidermal growth factor-stimulated prolactin expression and release in lactotrophs.

Authors:  Nira Ben-Jonathan; Shenglin Chen; Joseph A Dunckley; Christopher LaPensee; Sanjay Kansra
Journal:  Endocrinology       Date:  2008-10-01       Impact factor: 4.736

8.  The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.

Authors:  Jung Won Shin; Soohyun Kim; Suji Ha; Byungsan Choi; Seongyeong Kim; Seock-Ah Im; Tae-Young Yoon; Junho Chung
Journal:  Biomolecules       Date:  2019-10-19

9.  A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors.

Authors:  Y Meng; L Zheng; Y Yang; H Wang; J Dong; C Wang; Y Zhang; X Yu; L Wang; T Xia; D Zhang; Y Guo; B Li
Journal:  Oncogenesis       Date:  2016-03-21       Impact factor: 7.485

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.